Latest "Therapure Biopharma" News Stories

09:52 EDT 20th October 2018 | BioPortfolio

Here are the most relevant search results for "Therapure Biopharma" found in our extensive news archives from over 250 global news sources.

More Information about Therapure Biopharma on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Therapure Biopharma for you to read. Along with our medical data and news we also list Therapure Biopharma Clinical Trials, which are updated daily. BioPortfolio also has a large database of Therapure Biopharma Companies for you to search.

Showing "Therapure Biopharma" News Articles 1–25 of 2,500+

Extremely Relevant

Therapure Biopharma spins out Evolve Biologics


Therapure Biomanufacturing Announces U.S. FDA Approval for Manufacturing of Its Partner Insmed’s ARIKAYCE®

Therapure Biomanufacturing, an integrated contract development and manufacturing organization (CDMO) and a division of Therapure Biopharma Inc. (Therapure or the Company), today announced approval for the manufacturing of Insmed Incorporated’s ARIKAYCE® at

Therapure Biopharma Launches Biologics Division

New plasma products and technology company-Evolve Biologics-led by Blaine Forshage as CEO

Therapure Biomanufacturing Announces U.S. ...


Therapure Biopharma Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250

SummaryTherapure Biopharma Inc Therapure is a biopharmaceutical company that offers research and development services. The company's activities include manufacture, development, purification, and packaging of therapeutic proteins and followon biologics. It operates through its division therapure biomanufacturing, therapure innovations and therapure biologics. Therapure's therapure biomanufacturing...

Therapure Biopharma Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24072018] Prices from USD $250

SummaryTherapure Biopharma Inc Therapure is a biotherapeutics company that enhances patient care through its three divisions: therapure biomanufacturing, therapure innovations and evolve biologics. The company's therapure biomanufacturing division offers pipeline products such as TBI 301, TBI 302 and TBI 304H. Its company's therapure innovations operate as a proprietary drug development division a...

US FDA approves the manufacturing of rare lung disease treatment

Therapure was granted approval for the manufacture of Insmed Incorporatedâs drug Arikayce at its Missassauga, Canada facility.

KBI Biopharma: How to stand out in the CMO space

KBI Biopharma is a CMO focused exclusively on biologics. Bernardo Estupinan-Gaisbauer, Vice President – Business Development at KBI Biopharma, discusses their strategy for partnering, and the challenges of staying competitive in the CMO sector.

#jobs #lifescience Biopharma/Biotech

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Biopharma/Biotech .CA-South San Francisco, Biopharma/Biotech Company: Amgen, Inc. Location: South San Francisco, CA Position Type: Full Time Experience: Unspecified Education: Unspecified Amgen, Inc. has opptys in South San … Continue reading → Cet article #jobs #l...

Hillstream BioPharma looks forward to pre-IND discussion with FDA in Q4

Hillstream BioPharma CEO Randy Milby sits down with Proactive Investors' Christine Corrado at the BIO Investor Forum in San Francisco. Hillsteam BioPharma is developing targeted cancer therapeutics designed to be safer and more efficacious than currently available chemo-therapies.

Prestige Biopharma And Alvogen Announce License And Supply Agreement To Commercialize Biosimilar

NewsPrestige BioPharma and Alvogen have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar in Central and Eastern Europe.

#jobs #lifescience Director of Corporate Communications – Ph III Biopharma

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Director of Corporate Communications – Ph III Biopharma .MA-Lexington, If you are a Director of Corporate Communications with rare disease, ophthalmology, and/or nephrology experience, please read on! What … Continue reading → Cet article #jobs #lifescience D...

Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene

Tasly Biopharma paid $48 million in stock to buy out its China JV partner Transgene (P: TNG), which holds China rights to two Transgene products: T601, an oncolytic virus, and T101, a therapeutic vaccine. The stock represents 2.53% of Tasly Biopharma's capital after a pre-IPO investment round, which priced at the same time as the Transgene transaction. Tasly Biopharma, the novel drug subsidiary of...

Evolve Biologics™ Reaches Major Milestones in Phase III Trial for PlasmaCap™ IG (Intravenous Immunoglobulin), Including Dosing of First Pediatric Patient

Half of Required Infusions Now Successfully Administered in Adult Portion of Study A Prospective, Open-Label, Multicenter Study of the Efficacy, Safety, Tolerability and Pharmacokinetics of PlasmaCap IG in Adults and Children with Primary Immune Deficiency Diseases Evolve Biologics (“Evolve”), a division of Therapure Biopharma Inc. ...

#jobs #lifescience BioPharm/BioTech

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: BioPharm/BioTech .MA-Cambridge, BioPharma/BioTech BIOPHARMA/BIOTECH Amgen, Inc. has opptys in Cambridge, MA for a Sr Assoc (Ref #A4KQ5L); Engr Up to 25% domstc & int’l travel reqd (Ref #A57QHS). … Continue reading → Cet article #jobs #lifescience BioPhar...

How the US-Mexico trade deal could impact the biologics market

BioPharma-Reporter (BPR) discusses with Jennifer Fox (JF), co-chair of Brinks Gilson & Lioneâs biopharma practice group, the provisional detail revealed from the US administrationâs proposed trade deal with Mexico, and its potential impact on the biopharma industry.

REPORT: Biopharma Mfg. Capacity and Production

222 biopharma companies surveyed plus130 industry vendors and direct suppliers of materials

Integrated BioPharma, Inc.: Integrated Biopharma Announces Conversion of $5,350,000 Convertible Debt to Equity

HILLSIDE, NJ / ACCESSWIRE / August 1, 2018 / Integrated BioPharma, Inc. (OTCQB: INBP) (the "Company" or "INBP") announced today the conversion of its Amended and Restated Convertible Secured Promis...

RedHill BioPharma Receives New Patent

RedHill Biopharma received a notice of allowance from the US patent and Trademark Office on Monday (August 20) for a new formulation patent covering RHB-106, which will be valid until 2033. The post RedHill BioPharma Receives New Patent appeared first on Investing News Network.

New Disposable Control Valve Is Designed for BioPharma

This specialty instrument was developed in response to the biopharma industry’s rapidly expanding requirements

Top 5 Women Executives in the Biopharma Industry by Compensation

Not only are women generally underrepresented in the biopharma industry, but compared to many of the top male executives, underpaid. Here’s a closer look at the top five female executives by pay in the biopharma industry.

Array BioPharma Receives FDA Breakthrough Therapy Designation For Braftovi

NewsArray BioPharma Inc. received Breakthrough Therapy Designation from the FDA for encorafenib (BRAFTOVI), in combination with binimetinib (MEKTOVI) and cetuximab for the treatment of patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC).

Evolve Biologics™ Provides Update on Progress in Phase III Trial for PlasmaCap™ IG (Intravenous Immunoglobulin)

More than 80% of Required Infusions Now Successfully Administered in Adult Portion of Study Recruitment and Enrollment of Patients in Pediatric Portion of Study Continues to Proceed On Plan Abstracts on the Study and PlasmaCap EBA™ Technology Accepted for Presentation at Upcoming Immunoglobulin National Society (“IgNS”) Confe...

Tasly Biopharma Raises $84.5 Million in Pre-IPO Round

Tasly Biopharma of Shanghai raised $84.5 million in new capital from a group of investors that included Ally Bridge. The funding is a pre-IPO round as Tasly is planning to list on the Hong Kong Exchange. The investors received a 4.5% stake in Tasly Biopharma, implying a $1.9 billion pre-IPO valuation. Tasly Biopharma is a subsidiary of Tasly Pharma. As a separate part of the transaction, Transgene...

Sutro Biopharma: origins, platform technology and competitive advantage

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with William J Newell, Chief Executive Officer at Sutro Biopharma, a biopharma drug development firm They discuss the company's: • origins and business model • collaborations • platform technology, how it works and its advantages over its competitors’ platforms • plans for the future

Quick Search


News Quicklinks